Change 5-day change 1-year change 3-year change Capi.($)
-9.09%-9.09% - - 30.31M
+0.37%+7.15%-5.10%+2.52% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-0.90%+7.62%+13.04%+20.92% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average -0.12%+9.14%+77.65%+112.60% 25.57B
Weighted average by Cap. +1.01%+8.71%+88.85%+131.26%
Logo Ophthalix Inc
Wize Pharma Inc, formerly Ophthalix, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. The Company markets, sells and distributes a formula known as LO2A, which protects ocular surface tissues. LO2A is a drug developed for the treatment of DES and other ophthalmological illnesses, including conjunctivochalasis (CCH) and sjogren's syndrome (sjogren's).
Employees
-